# Bristol Myers Squibb (BMY) Forecast Calculator

Interactive five-year financial forecast and DCF for Bristol Myers Squibb. Adjust revenue growth, margins, capex, and WACC to update revenue, free cash flow, and enterprise value.

- Canonical: https://finamodel.com/companies/bristol-myers-squibb/forecast
- Industry: Healthcare
- Forecast start year: 2026

## Historical data

| Year | Revenue | Free cash flow | EBITDA | Net income |
|---:|---:|---:|---:|---:|
| 2021 | 26145000000 | 7374000000 | 6721000000 | 3439000000 |
| 2022 | 42518000000 | 13299000000 | 3509000000 | -9015000000 |
| 2023 | 46385000000 | 15234000000 | 18784000000 | 6994000000 |
| 2024 | 46159000000 | 11948000000 | 17989000000 | 6327000000 |
| 2025 | 45006000000 | 12651000000 | 18200000000 | 8025000000 |

## Frequently asked questions

### What is Bristol Myers Squibb's primary business focus?

Bristol Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for patients with serious diseases. The company specializes in therapeutic areas such as oncology, haematology, immunology, cardiovascular, and neuroscience.

### How does Bristol Myers Squibb generate its revenue, and what are its key product categories?

Bristol Myers Squibb generates revenue from its diverse portfolio of innovative medicines, tracked across three product groupings: the Growth Portfolio, Eliquis, and the Legacy Portfolio. The Growth Portfolio includes newer launch products like Reblozyl and Breyanzi, while Eliquis is a major cardiovascular blockbuster, and the Legacy Portfolio consists of mature products.

### What is the projected revenue growth rate for Bristol Myers Squibb in the financial model?

The financial model for Bristol Myers Squibb assumes a revenue growth rate of approximately 14.5%. This assumption is crucial for evaluating whether the rapid ramp-up of the Growth Portfolio can successfully offset revenue declines from patent cliffs.

### What is Bristol Myers Squibb's capital expenditure strategy, and what percentage of revenue is allocated to it?

Bristol Myers Squibb allocates approximately 2% to 3% of its revenue to capital expenditures annually, amounting to about $1.0 billion to $1.5 billion. Roughly 60% of this capex is for growth, focused on expanding biologics, cell therapy, and radiopharmaceutical manufacturing capacity.

### What is the main purpose of the Bristol Myers Squibb financial model, and what key challenges does it address?

The model's primary purpose is to evaluate Bristol Myers Squibb's equity valuation and cash flow generation capacity. It specifically tests whether the rapid ramp-up of its Growth Portfolio can successfully offset steep revenue declines from the Revlimid patent cliff and impending Medicare price negotiations for Eliquis.

### Can I download an Excel financial model for Bristol Myers Squibb, and what forecast horizon does it cover?

Yes, an Excel financial model for Bristol Myers Squibb is available for download. This model provides a forecast horizon covering fiscal years 2026 through 2030.